XTX Topco Ltd Acquires New Position in Zymeworks Inc. (NYSE:ZYME)

XTX Topco Ltd bought a new position in Zymeworks Inc. (NYSE:ZYME) in the 2nd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund bought 14,272 shares of the company’s stock, valued at approximately $121,000.

Several other hedge funds and other institutional investors have also recently made changes to their positions in the company. Rubric Capital Management LP raised its stake in shares of Zymeworks by 31.1% in the fourth quarter. Rubric Capital Management LP now owns 3,475,384 shares of the company’s stock worth $36,109,000 after purchasing an additional 823,990 shares during the last quarter. Pennant Investors LP bought a new position in Zymeworks during the 4th quarter valued at about $402,000. Wellington Management Group LLP lifted its stake in Zymeworks by 31.0% during the 4th quarter. Wellington Management Group LLP now owns 205,246 shares of the company’s stock valued at $2,133,000 after acquiring an additional 48,564 shares during the period. AlphaMark Advisors LLC purchased a new stake in shares of Zymeworks during the 1st quarter valued at about $32,000. Finally, China Universal Asset Management Co. Ltd. grew its stake in shares of Zymeworks by 66.0% in the first quarter. China Universal Asset Management Co. Ltd. now owns 13,444 shares of the company’s stock worth $141,000 after acquiring an additional 5,344 shares during the period. Institutional investors own 92.89% of the company’s stock.

Zymeworks Trading Down 1.6 %

Shares of NYSE ZYME opened at $12.35 on Wednesday. Zymeworks Inc. has a 12-month low of $6.01 and a 12-month high of $13.27. The firm has a market capitalization of $873.21 million, a price-to-earnings ratio of -6.90 and a beta of 1.19. The firm has a 50 day moving average of $11.33 and a 200 day moving average of $9.94.

Zymeworks (NYSE:ZYME) last issued its quarterly earnings data on Thursday, August 1st. The company reported ($0.26) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.27) by $0.01. Zymeworks had a negative net margin of 179.42% and a negative return on equity of 21.97%. The firm had revenue of $19.24 million during the quarter, compared to the consensus estimate of $23.16 million. During the same quarter in the previous year, the firm posted ($0.76) EPS. Sell-side analysts predict that Zymeworks Inc. will post -0.85 EPS for the current year.

Analyst Upgrades and Downgrades

A number of research analysts recently weighed in on ZYME shares. Stifel Nicolaus increased their price objective on shares of Zymeworks from $20.00 to $21.00 and gave the company a “buy” rating in a research report on Friday, August 2nd. HC Wainwright increased their price target on Zymeworks from $10.00 to $12.00 and gave the company a “neutral” rating in a report on Wednesday, September 25th.

About Zymeworks

Zymeworks Inc, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company's lead product candidates include zanidatamab, a human epidermal growth factor receptor 2 (HER2) that is in Phase 1, Phase 2, and Phase 3 clinical trials, including certain ongoing pivotal clinical trials; and zanidatamab zovodotin, a HER2 -targeted antibody-drug conjugate that is in Phase 2 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors.